Descriptive analyses of safety data for anti-TNF therapies using related outcomes from Uppsala Monitoring Centre (UMC) of World Health Organization (WHO);Análise descritiva da segurança das drogas anti-TNF utilizando dados do Centro Colaborativo Internacional de Monitoramento de Medicamentos, o Uppsala Monitoring Centre (UMC) da Organização Mundial da Saúde (OMS)

Revista Brasileira de Medicina

Volumn 64, Issue 7, 2007, Pages 323-333

  Wong, Anthony ^a,b   Fonseca, Marcelo C M ^c   Sandron, Cristina Andrusaitis ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CEATOX Centro de Assistência Toxicológica

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adalimumab; Etanercept; Infliximab; Pharmacovigilance; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ABDOMINAL PAIN; ABNORMAL VISION; ABSCESS; ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANURIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BLEEDING; BLINDNESS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BREAST CANCER; BRONCHITIS; CELLULITIS; CEREBROVASCULAR DISEASE; CHOLELITHIASIS; COMPLEMENT FACTOR; CONFUSION; CONJUNCTIVITIS; CONVULSION; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; COUGHING; CYSTITIS; DEHYDRATION; DEMYELINATION; DEPERSONALIZATION; DEPRESSION; DERMATITIS; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; ERYTHEMA; FACE EDEMA; FEVER; GRANULOCYTOPENIA; HEADACHE; HEARING DISORDER; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HEMATURIA; HEMOLYTIC ANEMIA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPESTHESIA; HYPOACUSIS; HYPOTENSION; INFECTION; INGUINAL HERNIA; INJECTION SITE BLEEDING; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE REACTION; INSOMNIA; IRON DEFICIENCY ANEMIA; KIDNEY CYST; KIDNEY DYSFUNCTION; LACTATION; LEUKOCYTOSIS; LEUKOPENIA; LEUKORRHEA; LIVER DYSFUNCTION; LUNG EMBOLISM; LYMPHADENOPATHY; LYMPHOCYTOSIS; LYMPHOMA; MASTALGIA; MENORRHAGIA; MENSTRUATION DISORDER; MITRAL VALVE REGURGITATION; MUSCLE RIGIDITY; MYCOSIS; NAUSEA; OTALGIA; PAIN; PANCYTOPENIA; PARESTHESIA; PENIS DISEASE; PERICARDITIS; PERIPHERAL ISCHEMIA; PHARYNGITIS; PNEUMONIA; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PRURITUS; PSORIASIS; PURPURA; QT PROLONGATION; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SPLENOMEGALY; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; URINARY TRACT INFECTION; URTICARIA; UTERINE CERVIX DYSPLASIA; VAGINA BLEEDING; VAGINITIS; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASCULITIS; VASODILATATION; VESTIBULAR DISORDER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 34547818227     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26(1):6-14.
2. Lequerre T, Vittecoq O, Klemmer N, Goeb V, Pouplin S, Menard JF, Daragon A, Mejjad O, Le Loet X. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol. 2006;33(7):1307-14.
3. Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2(6):266-72.
4. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. 2001;44(12):2707-10.
5. Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. Cardiol Rev. 2006;14(1):50-2
6. Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease. World J Gastroenterol. 2006;12(38):6235-8.
7. Sood A, Midha V. Symptomatic sinus bradycardia with infliximab. Indian J Gastroenterol. 2004; 23(3):118-9.
8. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50(4):1040-50.
9. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807-11.
10. Doria A, Sarzi Puttini PC, Shoenfeld Y. Heart, rheumatism and autoimmunity: Milan, Italy. February 5-7, 2004. Autoimmun Rev. 2004;3(4):337-54.
11. Pearce BD, Hobbs MV, McGraw TS, Buchmeier MJ. Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. J Virol. 1994;68(9):5483-95.
12. Ruby J, Bluethmann H, Peschon JJ. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med. 1997 3;186(9):1591-6.
13. Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S108-14.
14. th ed. Florida, Churchill Livingstone 2000: 1645-9.
15. Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol. 2005;53(5 Suppl 1):S260-2.
16. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000;27(4):841-50.
17. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, anti-histamine pretreatment, and infusion number. J Rheumatol. 2004;31(10):1912-7.
18. Culy CR, Keating GM. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. BioDrugs. 2003;17(2):139-45.
19. Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10(19):6528-34.
20. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs. 2002;62(17):2493-537.
21. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-85.
22. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2757-64.
23. Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, Wallis WJ. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005;141(7):861-4.
24. Schiemann U, Kellner H. Gastrointestinal side effects in the therapy of rheumatologic diseases. Z Gastroenterol. 2002;40(11):937-43.
25. U.S. Food and Drugs Administration: Warning on severe hepatotoxicity with Remicade. Rockville, MD, US Food and Drugs Administration MedWatch, 2004.
26. Patel TR, Patel KN, Boyarsky AH. Staphylococcal liver abscess and acute cholecystitis in a patient with Crohn's disease receiving infliximab. J Gastrointest Surg. 2006;10(1):105-10.
27. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001;22(5):619-24.
28. Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, Rahman MU. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005;53(3):337-42.
29. Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity. 2005;38(2):155-60.
30. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNF-alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005;14(12):931-7.
31. Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol. 2006;33(1):24-30.
32. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545-51.
33. Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int. 2006;26(3):209-14.
34. Nancey S, Blanvillain E, Parmentier B, Flourie B, Bayet C, Bienvenu J, Fabien N. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis. 2005;11(11):986-91.
35. Straub RH, Pongratz G, Scholmerich J, Kees F, Schaible TF, Antoni C, Kalden JR, Lorenz HM. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. Arthritis Rheum. 2003;48(6):1504-12.
36. Holden RJ, Pakula IS. The role of tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity. Med Hypotheses 1996;47(6):423-38.
37. Barber J, Sheeran T, Mulherin D. Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis. Ann Rheum Dis. 2003;62(5):490-1.
38. Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, Naiman SC. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol. 2003;71(5):396-8.
39. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003;139(3):W-W63.
40. Eklund KK, Peltomaa R, Leirisalo-Repo M. Occurrence of pulmonary thromboembolism during infliximab therapy. Clin Exp Rheumatol. 2003; 21(5):679.
41. Ferraccioli G, Gremese E. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. Autoimmun Rev. 2004;3(4):261-6.
42. Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G. Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol. 2006;12(5):249-51.
43. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20(7):1400-6.
44. Doulton TW, Tucker B, Reardon J, Velasco N. Anti-neutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62(3):234-8.
45. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50(10):3161-9.
46. Hannuksela M. Cutaneous rash from the use of medicine for rheumatoid arthritis. Duodecim. 2006;122(1):105, 111.
47. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med. 1999; 131(8):634.
48. Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, Samuels A, Oghilikhan M, Gaspari A. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142(2):198-202.
49. de Groot M, de Rie MA, Bos JD. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris. Br J Dermatol. 2005;153(4):843-4.
50. Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2003;30(11):2506-7.
51. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223-31.
52. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol. 2007 26(5): 787-8.
53. Cachafeiro-Vilar A, Garcia-Padilla C, Reyes E, Hernandez-Molina G. Polyarticular arthritis secondary to Mycobacterium bovis infection: an unusual clinical presentation. Joint Bone Spine. 2007; 74(1):107-9.
54. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007 Mar 6; [Epub ahead of print].
55. Michaud K, Wolfe F. The association of rheumatoid arthritis and its treatment with sinus disease. J Rheumatol. 2006;33(12):2412-5.
56. Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004;122(5):793-4.
57. Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci. 2006;244(1-2):133-6.
58. Tauber T, Turetz J, Barash J, Avni I, Morad Y. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006;10(1):26-9.